EMA review of suicide risk for Ozempic, Saxenda extended to other GLP-1 receptor agonists | Biospace
Pictured: The EMA building at its old headquarters in London/iStock, Lubo Ivanko The European Medicines Agency has extended its review of a potential suicide risk associated with Novo Nordisk’s Ozempic and Saxenda to other GLP-1 receptor agonists used for weight loss and the treatment of type 2 diabetes. The review was initiated by the Icelandic … Read more
